BIIB vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Nov 10, 2026
BIIB
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | BIIB | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 16.0772 | 9.8522 | GSK |
| PEG Ratio | 3.383 | 6.3543 | BIIB |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 10.6% | 4.0% | BIIB |
| Earnings Growth | -84.8% | -22.8% | GSK |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 38.4/100 | 47.1/100 | GSK |
| Profit Margin | 3.4% | 13.0% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | BUY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
BIIB
MarkupPrice above SMA50, rising 50-day trend (6.2% over 20 days), RSI 60
GSK
NeutralMixed signals - no dominant trend phase, RSI 53
Fundamentals Snapshot
| Metric | BIIB | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 15.6 | 10.3 |
| Trailing P/E | 107.5 | 18.0 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.8% | 0.7% |
| Operating Margin | 0.2% | 0.3% |
| EPS | 2.37 | 2.87 |
| Dividend Yield | — | 0.04% |